These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17256140)

  • 21. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?
    Khorjekar GR; Van Nostrand D; Garcia C; O'Neil J; Moreau S; Atkins FB; Mete M; Orquiza MH; Burman K; Wartofsky L
    Thyroid; 2014 Sep; 24(9):1394-9. PubMed ID: 24820222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
    Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations.
    Ramanna L; Waxman A; Braunstein G
    J Nucl Med; 1991 Mar; 32(3):441-6. PubMed ID: 2005453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of technetium scintigraphy and iodine uptake measurement during follow-up of differentiated thyroid cancer.
    Caglar M; Tuncel M; Alpar R
    Ann Nucl Med; 2004 Sep; 18(6):479-82. PubMed ID: 15515746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans.
    Zanotti-Fregonara P; Keller I; Rubello D; Calzada-Nocaudie M; Devaux JY; Hindié E
    J Endocrinol Invest; 2009 Mar; 32(3):267-71. PubMed ID: 19542747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin.
    Niederkohr RD; McDougall IR
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):363-7. PubMed ID: 17021814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of serum thyroglobulin measurements and whole body 131I scanning in the management of treated differentiated thyroid carcinoma.
    Galligan JP; Winship J; van Doorn T; Mortimer RH
    Aust N Z J Med; 1982 Aug; 12(4):248-54. PubMed ID: 6814409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
    Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
    Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
    Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
    Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isotope imaging for metastatic thyroid cancer.
    Haugen BR; Lin EC
    Endocrinol Metab Clin North Am; 2001 Jun; 30(2):469-92. PubMed ID: 11444171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
    Lindegaard MW; Paus E; Høie J; Kullman G; Stenwig AE
    Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning.
    Caballero-Calabuig E; Cano-Terol C; Sopena-Monforte R; Reyes-Ojeda D; Abreu-Sánchez P; Ferrer-Rebolleda J; Sopena-Novales P; Plancha-Mansanet C; Félix-Fontestad J
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1449-56. PubMed ID: 18418591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D; Mazzarotto R; Casara D
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of 123I in Diagnostic Radioactive Iodine Scans in Children with Differentiated Thyroid Carcinoma.
    Schoelwer MJ; Zimmerman D; Shore RM; Josefson JL
    Thyroid; 2015 Aug; 25(8):935-41. PubMed ID: 25978106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
    Ma C; Xie J; Kuang A
    J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.